IMMUNOMODULATORY AGENTS AND PROTEASOME INHIBITORS IN THE TREATMENT OF MULTIPLE MYELOMA

被引：9
|
作者：
Noonan, Kimberly [1 ]
Colson, Kathleen [1 ]
机构：
[1] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA
来源：
SEMINARS IN ONCOLOGY NURSING | 2017年 / 33卷 / 03期
关键词：
multiple myeloma; immunomodulatory drugs; proteasome inhibitors; treatment; side effects; LENALIDOMIDE PLUS DEXAMETHASONE; STEM-CELL TRANSPLANTATION; LOW-DOSE DEXAMETHASONE; NEWLY-DIAGNOSED MYELOMA; LONG-TERM SURVIVAL; ELDERLY-PATIENTS; OPEN-LABEL; CONSENSUS STATEMENT; ANTITUMOR-ACTIVITY; ORAL MELPHALAN;
D O I：
10.1016/j.soncn.2017.05.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OBJECTIVE: To review the current evidence on the use of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) in the treatment of multiple myeloma (MM). DATA SOURCES: Journal articles, research reports, state of the science papers, and clinical guidelines. CONCLUSION: There has been a tremendous increase of new agents to treat multiple myeloma in the last 15 years. The IMiDs and PIs remain essential components of many anti-myeloma regimens. IMPLICATIONS FOR NURSING PRACTICE: With these advances in the therapeutic landscape, knowledge of these drugs, side effects and nursing implications are essential to improve outcomes. Patient education is also of vital importance in achieving optimal responses to treatment.
引用
下载
收藏
页码：279 / 291
页数：13
相关论文
共 50 条
  • [11] The proteasome and proteasome inhibitors in multiple myeloma
    Sara Gandolfi
    Jacob P. Laubach
    Teru Hideshima
    Dharminder Chauhan
    Kenneth C. Anderson
    Paul G. Richardson
    Cancer and Metastasis Reviews, 2017, 36 : 561 - 584
  • [12] The proteasome and proteasome inhibitors in multiple myeloma
    Gandolfi, Sara
    Laubach, Jacob P.
    Hideshima, Teru
    Chauhan, Dharminder
    Anderson, Kenneth C.
    Richardson, Paul G.
    CANCER AND METASTASIS REVIEWS, 2017, 36 (04) : 561 - 584
  • [13] Immunomodulatory agents changing the landscape of multiple myeloma treatment
    Niesvizky, Ruben
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 88 : S1 - S4
  • [14] Immunomodulatory Agents for Multiple Myeloma
    Minarik, Jiri
    Sevcikova, Sabina
    CANCERS, 2022, 14 (23)
  • [15] Use of proteasome inhibitors in the treatment of patients with multiple myeloma
    Rukavitsyn, O. A.
    TERAPEVTICHESKII ARKHIV, 2006, 78 (10): : 40 - 44
  • [16] Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
    Merin, Noah M.
    Kelly, Kevin R.
    PHARMACEUTICALS, 2015, 8 (01) : 1 - 20
  • [17] Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma
    Baljevic, Muhamed
    Orlowski, Robert Z.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (06) : 459 - 473
  • [18] Proteasome inhibitors for multiple myeloma
    Okazuka, Kiyoshi
    Ishida, Tadao
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (09) : 785 - 792
  • [19] Proteasome Inhibitors in Multiple Myeloma
    Anderson, Kenneth C.
    SEMINARS IN ONCOLOGY, 2009, 36 (02) : S20 - S26
  • [20] EFFICACY OF RETREATMENT WITH IMMUNOMODULATORY DRUGS AND PROTEASOME INHIBITORS FOLLOWING DARATUMUMAB TREATMENT IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS
    Oostvogels, R.
    Jak, M.
    Minnema, M. C.
    HAEMATOLOGICA, 2018, 103 : 33 - 33
12345